Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.
2.

The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.

Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R Sr, Mortillo S, Wautlet BS, Krishnan B, Kukral D, Malone H, Lewin AC, Henley BJ, Fargnoli J.

Mol Cancer Ther. 2010 Feb;9(2):369-78. doi: 10.1158/1535-7163.MCT-09-0472. Epub 2010 Jan 26.

3.

Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.

Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, Jordan VC.

Eur J Cancer. 2010 Jun;46(9):1537-53. doi: 10.1016/j.ejca.2010.02.018. Epub 2010 Mar 18.

4.

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.

Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E.

Clin Cancer Res. 2008 Oct 1;14(19):6146-53. doi: 10.1158/1078-0432.CCR-08-0509.

5.

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.

Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J.

Cancer Chemother Pharmacol. 2009 Dec;65(1):55-66. doi: 10.1007/s00280-009-1002-0. Epub 2009 Apr 26.

PMID:
19396600
6.

Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.

Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L.

Breast Cancer Res Treat. 2010 Oct;123(3):747-55. doi: 10.1007/s10549-009-0677-6. Epub 2009 Dec 19.

PMID:
20024612
7.

Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.

Lin HC, Huang YT, Yang YY, Lee PC, Hwang LH, Lee WP, Kuo YJ, Lee KC, Hsieh YC, Liu RS.

J Gastroenterol Hepatol. 2014 May;29(5):1073-82. doi: 10.1111/jgh.12480.

PMID:
24325631
8.

Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.

Dempke WC, Zippel R.

Anticancer Res. 2010 Nov;30(11):4477-83. Review.

PMID:
21115896
9.

Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).

Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan R Sr, Kukral DW, Kamath A, Marathe P, D'Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.

J Med Chem. 2008 Mar 27;51(6):1976-80. doi: 10.1021/jm7013309. Epub 2008 Feb 21.

PMID:
18288793
10.

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.

Clin Cancer Res. 2003 Apr;9(4):1546-56.

11.

Brivanib alaninate for cancer.

Diaz-Padilla I, Siu LL.

Expert Opin Investig Drugs. 2011 Apr;20(4):577-86. doi: 10.1517/13543784.2011.565329. Epub 2011 Mar 11. Review.

PMID:
21391890
12.

Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.

Gong J, Gan J, Masson E, Syed S, Xia YQ, Williams D, Pursley J, Jemal M, Humphreys WG, Iyer RA.

Drug Metab Dispos. 2012 Dec;40(12):2374-80. doi: 10.1124/dmd.112.047340. Epub 2012 Sep 14.

13.

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL.

Cell Physiol Biochem. 2011;27(5):565-74. doi: 10.1159/000329978. Epub 2011 Jun 15.

PMID:
21691074
14.

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG.

Cancer Res. 2003 Nov 1;63(21):7301-9.

15.

Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.

Syed S, Clemens PL, Lathers D, Kollia G, Dhar A, Walters I, Masson E.

J Clin Pharmacol. 2012 Jun;52(6):914-21. doi: 10.1177/0091270011407495. Epub 2011 Jun 9.

PMID:
21659627
16.

Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.

Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, Tran SB, Iyer RA.

Drug Metab Dispos. 2011 May;39(5):891-903. doi: 10.1124/dmd.110.037341. Epub 2011 Feb 2.

17.

Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.

Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R Sr, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.

J Med Chem. 2005 Jun 16;48(12):3991-4008.

PMID:
15943473
18.

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.

LaMontagne KR, Butler J, Borowski VB, Fuentes-Pesquera AR, Blevitt JM, Huang S, Li R, Connolly PJ, Greenberger LM.

Angiogenesis. 2009;12(3):287-96. doi: 10.1007/s10456-009-9151-7. Epub 2009 Jun 21.

PMID:
19544081
19.

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.

Allen E, Walters IB, Hanahan D.

Clin Cancer Res. 2011 Aug 15;17(16):5299-310. doi: 10.1158/1078-0432.CCR-10-2847. Epub 2011 May 27.

20.

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.

Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DS, Galbraith S.

Ann Oncol. 2011 Jun;22(6):1413-9. doi: 10.1093/annonc/mdq599. Epub 2010 Dec 3.

Items per page

Supplemental Content

Write to the Help Desk